ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response.
This report describes a case of large-cell lung carcinoma with neuroendocrine features, presenting with the full clinical picture of paraneoplastic opsoclonus-myoclonus syndrome. The patient had an unexpectedly dramatic resolution of the neurologic dysfunction after receiving antineoplastic treatment. Symptom improvement paralleled a progressive decline of serum ANNA-2 antibody titers to undetectable levels.
Erlich
Rodrigo
R
Department of Oncology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave., Baltimore, MD 21224, USA. rerlich@jhmi.edu
Morrison
Candis
C
Kim
Bong
B
Gilbert
Mark R
MR
Alrajab
Saadah
S
D000974:Antibodies, Antinuclear; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D008875:Middle Aged; D020361:Paraneoplastic Syndromes, Nervous System / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D011379:Prognosis; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear; D000912:Antibodies, Neoplasm; C487483:ANNA-2 antibody